Investor Presentaiton slide image

Investor Presentaiton

National reimbursement in Japan & lab launch in China taps into large global market Japan Potential for rapid growth: 1M new cancer cases per year¹, centralized care, <10% penetration of CGP market² Driving business: National reimbursement approval from the Japanese MHLW for Guardant360 CDx + efficient local sales model + strong ASP China Point of differentiation: China is a critical, strategic market for biopharma partnerships Strategic partnership for growth: 30+ biopharma clients have engaged with Guardant since partnership with Adicon lab INVESTOR 20 DAY 23 GUARDANT 93 1.International Agency for Research on Cancer. Japan. Globocan 2020. https://gco.iarc.fr/toaday/data/factsheets/populations/392-japan-fact-sheets.pdf 2. Japan C-CAT database
View entire presentation